 Cytochrome P-450 CYP3A Inhibitors
"Cytochrome P-450 CYP3A Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A.
| Descriptor ID |
D065692
|
| MeSH Number(s) |
D27.505.389.500.503 D27.505.519.389.335.503
|
| Concept/Terms |
Cytochrome P-450 CYP3A Inhibitors- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P 450 CYP3A Inhibitors
- CYP3A Inhibitors
- Inhibitors, CYP3A
- P450 CYP3A Inhibitors
- Inhibitors, P450 CYP3A
Cytochrome P-450 CYP3A7 Inhibitors- Cytochrome P-450 CYP3A7 Inhibitors
- Cytochrome P 450 CYP3A7 Inhibitors
- P450 CYP3A7 Inhibitors
- CYP3A7 Inhibitors, P450
- Inhibitors, P450 CYP3A7
- CYP3A7 Inhibitors
- Inhibitors, CYP3A7
Cytochrome P-450 CYP3A5 Inhibitors- Cytochrome P-450 CYP3A5 Inhibitors
- Cytochrome P 450 CYP3A5 Inhibitors
- P450 CYP3A5 Inhibitors
- CYP3A5 Inhibitors, P450
- CYP3A5 Inhibitors
- Inhibitors, CYP3A5
Cytochrome P-450 CYP3A4 Inhibitors- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P 450 CYP3A4 Inhibitors
- P450 CYP3A4 Inhibitors
- Inhibitors, P450 CYP3A4
- CYP3A4 Inhibitors
- Inhibitors, CYP3A4
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP3A Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP3A Inhibitors".
This graph shows the total number of publications written about "Cytochrome P-450 CYP3A Inhibitors" by people in this website by year, and whether "Cytochrome P-450 CYP3A Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 2 | 2 | | 2013 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 1 | 0 | 1 | | 2021 | 3 | 0 | 3 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP3A Inhibitors" by people in Profiles.
-
Work HM, Hackett JC, Lampe JN. HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation. Drug Metab Dispos. 2024 May 16; 52(6):516-525.
-
Work HM, Kandel SE, Lampe JN. Characterization of fluorescent probe substrates to develop an efficient high-throughput assay for neonatal hepatic CYP3A7 inhibition screening. Sci Rep. 2021 09 30; 11(1):19443.
-
Francis J, Mngqibisa R, McIlleron H, Kendall MA, Wu X, Dooley KE, Firnhaber C, Godfrey C, Cohn SE, Denti P. A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clin Pharmacol Ther. 2021 10; 110(4):1057-1065.
-
Kandel SE, Lampe JN. Inhibition of CYP3A7 DHEA-S Oxidation by Lopinavir and Ritonavir: An Alternative Mechanism for Adrenal Impairment in HIV Antiretroviral-Treated Neonates. Chem Res Toxicol. 2021 04 19; 34(4):1150-1160.
-
Rosenthal P, Narkewicz MR, Yao BB, Jolley CD, Lobritto SJ, Wen J, Molleston JP, Hsu EK, Jonas MM, Zha J, Liu L, Leung DH. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a. Adv Ther. 2020 07; 37(7):3299-3310.
-
Li H, Lampe JN. Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism. Arch Biochem Biophys. 2019 09 30; 673:108078.
-
Ramsden D, Fung C, Hariparsad N, Kenny JR, Mohutsky M, Parrott NJ, Robertson S, Tweedie DJ. Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates. Drug Metab Dispos. 2019 10; 47(10):1206-1221.
-
Garg V, Shen J, Li C, Agarwal S, Gebre A, Robertson S, Huang J, Han L, Jiang L, Stephan K, Wang LT, Lekstrom-Himes J. Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor. Clin Transl Sci. 2019 05; 12(3):267-275.
-
Ou Y, Xu Y, Gore L, Harvey RD, Mita A, Papadopoulos KP, Wang Z, Cutler RE, Pinchasik DE, Tsimberidou AM. Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. Br J Clin Pharmacol. 2019 03; 85(3):530-539.
-
Gordon LA, Kumar P, Brooks KM, Kellogg A, McManus M, Alfaro RM, Nghiem K, George JM, Lozier J, Penzak SR, Hadigan C. Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers. Circulation. 2016 12 06; 134(23):1909-1911.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|